PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations

The anti-PD-L1 monoclonal antibody (mAb) targeting PD-1/PD-L1 immune checkpoint has achieved outstanding results in clinical application and has become one of the most popular anti-cancer drugs. The mechanism of molecular recognition and inhibition of PD-L1 mAbs is not yet clear, which hinders the s...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xin, Yan, Xiao, Zhuo, Wei, Gu, Jinke, Zuo, Ke, Liu, Wei, Liang, Li, Gan, Ya, He, Gang, Wan, Hua, Gou, Xiaojun, Shi, Hubing, Hu, Jianping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073277/
https://www.ncbi.nlm.nih.gov/pubmed/29986511
http://dx.doi.org/10.3390/ijms19071984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073277/
https://www.ncbi.nlm.nih.gov/pubmed/29986511
http://dx.doi.org/10.3390/ijms19071984

Ejemplares similares